Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna Inc

Moderna Moves Forward With Second HIV Vaccine Trial

Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble…

Benzinga

GeoVax Labs Retains CATO SMS To Manage Its Mid-Stage COVID-19 Vaccine Trials

GeoVax Labs Inc (NASDAQ:GOVX) has engaged CATO SMS to manage its two ongoing Phase 2 trials of its COVID-19 vaccine candidate, GEO-CM04S1. One is testing the safety and effectiveness of GEO-CM04S1 compared to the Pfizer Inc (NASDAQ:PFE) / BioNTech SE (NASDAQ:BNTX) in immunosuppressed patients with blood cancer. The other trial is testing GEO-CM04S1 as a booster in…

Benzinga

Here's Why Moderna Shares Are Rising On Monday

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 18.9% at $164.27 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna Starts Dosing In Mid-Stage Omicron-Specific Bivalent Booster Candidate

Moderna Inc (NASDAQ: MRNA) has

Benzinga

Moderna Plans Vaccines Against 15 Pathogens With Future Pandemic Potential

Moderna Inc (NASDAQ: MRNA) plans to develop and begin testing vaccines targeting 15 pathogens identified as the biggest public health risk by WHO and CEPI by 2025. The Company also said it would permanently wave its COVID-19 vaccine patents for shots intended for certain low- and middle-income countries. At its global public health strategy,…

Benzinga

Moderna To Set Up mRNA Vaccine Manufacturing Facility In Kenya

Moderna Inc (NASDAQ:MRNA) would set up a manufacturing facility in Kenya, its first in Africa, to produce messenger RNA (mRNA) vaccines, including COVID-19 shots. Moderna expects to invest about $500 million in the Kenyan facility and supply as many as 500 million doses of mRNA vaccines to the continent each year. It also…

Benzinga

Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s)

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Genevant have sued Moderna Inc (NASDAQ: MRNA) for

Benzinga

Read news from The Economist, FT, and more,
with one subscription

(MRNA) - Analyzing Moderna Inc's Short Interest

Moderna Inc's (NASDAQ:MRNA) short percent of float has fallen 5.45% since its last report. The company recently reported that it has 15.80 million shares sold short, which is 4.51% of all regular shares that are available for trading.

Benzinga

Will Moderna Be 'One Of The Most Valuable Healthcare Companies' In The World? Steve Weiss Believes So

Moderna Inc (NASDAQ: MRNA) is on the move Thursday following strong quarterly financial results. Short Hills Capital's Steve Weiss decided to pick up additional shares of the commercial-stage biotech company after the report.

Benzinga

What's Going On With Moderna Shares Today?

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 9.7% at $149.11 after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Benzinga

Moderna Beats On Q4 Earnings, Announces $3B Buyback; Expects ~$19B In FY22 COVID-19 Vax Sales

Moderna Inc (NASDAQ:MRNA) reports a Q4 EPS of $11.29, a turnaround from an EPS loss of $(0.69) a year ago, beating the consensus estimate of $9.90. The Company clocked Q4 revenues of $7.21 billion compared to just $571 million a year ago, beating the consensus of $6.79 billion. Product sales were $6.9…

Benzinga

Moderna, Thermo Fisher Join Forces To Manufacture COVID-19 Vaccine, Other Drugs

Moderna Inc (NASDAQ: MRNA) has en

Benzinga

Looking Into Moderna Inc's Recent Short Interest

Benzinga

Moderna Adds Three New mRNA-Based Development Programs To Its Pipeline

Moderna Inc (NASDAQ: MRNA) said it is deve

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Moderna Says COVID-19 Booster To Be Ready By August, But Dicey If Omicron-Specific Needed: Reuters

Moderna Inc's (NASDAQ: MRNA) CEO, Stephane Bancel, told Reuters that an

Benzinga

Pfizer, Moderna COVID-19 Boosters Effectiveness Wanes After Four Months: CDC Study

COVID-19 vaccine boosters from Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ:

Benzinga

Moderna CEO Sells Shares, Deletes Social Media: What You Need To Know

Moderna Inc (NASDAQ: MRNA) shares are down more than 40% since the start of the year and continue to trend lower Monday.

Benzinga

Why Moderna Shares Are Rising Today

Moderna Inc (NASDAQ: MRNA) is trading higher Monday after the U.S. Food and Drug Administration approved the Biologics License Application for SPIKEVAX to prevent COVID-19 in individuals 18 years of age and older.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Moderna's COVID-19 Vaccine Becomes Second To Score Complete FDA Approval

The FDA has given complete approval to Moderna Inc's (NASDAQ:

Benzinga

IAVI, Moderna Kickstart HIV Vaccine Antigens Trial Delivered Through mRNA Technology

IAVI, the nonprofit scientific research organization, and Moderna Inc (NASDAQ: MRNA) have

Benzinga

After Pfizer, Moderna Kickstarts Omicron-Targeted COVID-19 Vaccine Trial

Moderna Inc (NASDAQ: MRNA) has started a mid-stage study, testing a booster dose of its COVID-19 vaccine specifically

Benzinga

Why Moderna Shares Are Rising

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 7.2% at $163.54 Wednesday afternoon after Deutsche Bank upgraded the stock from Sell to Hold and announced a $175 price target.

Benzinga

Peering Into Moderna Inc's Recent Short Interest

Moderna Inc's (NASDAQ:MRNA) short percent of float has risen 8.66% since last its last report. The company recently reported that it has 16.69 million shares sold short, which is 4.77% of all regular shares that are available for trading.

Benzinga

Why Moderna, Pfizer, BioNTech And Novavax Shares Are Falling Today

Shares of vaccine makers, including Moderna Inc (NASDAQ: MRNA), BioNTech SE - ADR (NASDAQ: BNTX) and Novavax, Inc.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

National Institutes of Health

National Institute of Allergy and Infectious Diseases

18 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.